67 Scopus citations

Abstract

Methotrexate (MTX) remains the most commonly used disease modifying antirheumatic drug in rheumatoid arthritis (RA) because of its cost and experience in its use, despite the availability of new treatments such as leflunomide and the biological agents. However, a significant number of patients with RA either do not benefit from the drug or are unable to tolerate it. Pharmacogenetic approaches may help optimise treatment with MTX, and also other agents, in RA.

Original languageEnglish
Pages (from-to)4-9
Number of pages6
JournalAnnals of the Rheumatic Diseases
Volume62
Issue number1
DOIs
StatePublished - Jan 1 2003

Fingerprint

Dive into the research topics of 'Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?'. Together they form a unique fingerprint.

Cite this